Interesting ISRG Put And Call Options For February 2026

Intuitive Surgical (ISRG) is the subject of two options trade ideas: a $555 put with a bid of $18.90 (implying a cash purchase basis of $536.10 vs the current $571.05 share price) and a $580 call with a bid of $24.50 used for a covered-call strategy. Analytics place the probability the $555 put expires worthless at ~62% (YieldBoost 3.41% or 28.25% annualized) and the $580 call at ~51% (4.29% boost or 35.59% annualized if it expires worthless); implied volatilities are ~37% (put) and 38% (call) versus a 12-month realized volatility of 36%. The call example assumes a February 2026 expiration and highlights tradeoffs between immediate yield and capped upside for shareholders.

Analysis

Market structure: The option pricing on ISRG (Feb 2026 555 put bid 18.90; 580 call bid 24.50) signals a market that is willing to monetize ownership risk rather than take directional exposure — implied vol ~37–38% vs realized 36% implies little premium for tails. Winners are premium sellers (income strategies) and long-term holders who can be patient for assignment; losers are directional momentum traders who are capped by covered calls or forced into ownership via puts. Cross-asset: meaningful put selling into a single large-cap healthcare name is neutral for rates/FX but concentrates gamma risk in equities — a sudden sell-off could spike IV and push funding needs for option sellers.

Risk assessment: Tail risks include device recalls, reimbursement shocks, or a negative clinical/regulatory event that could drop shares >30% (low-probability, high-impact). Short-term (days–weeks) risks are IV spikes around catalysts; medium-term (months) is surgical volume cyclicality and competitor product launches; long-term (years) is market-share erosion from entrants. Hidden dependencies: large-scale put selling can create asymmetric buying demand on downturns (pinning risk) and basis risk if assigned; options-implied odds (62% put OTM) can change rapidly with a 5–10% move. Key catalysts: quarterly surgical volumes (next 60–90 days), new product approvals, and macro healthcare spending shifts.

Trade implications: Direct tactical plays: cash-secured Feb 2026 555 puts if willing to own at 536.10 (collect 18.90) sized 1–3% NAV with stop/roll if IV rises >5pt or stock falls >12% within 90 days. Covered-call pick: buy ISRG and sell Feb 2026 580 calls to generate ~5.9% capped return; use for tax/wrap accounts or yield buckets. Volatility trades: sell calendars/diagonals if IV > realized by >3pt and no near-term catalyst; buy a protective put (collar) if downside protection required.

Contrarian angles: The market is underpricing the structural upside from procedure mix shift to robotics — if adoption accelerates, calls will reprice fast and sellers will suffer pain (IV repricing >10pt possible). Conversely, the consensus income trade (selling long-dated premium) underestimates assignment concentration risk; a forced mass assignment into a falling market could lead to chaotic rebalancing. Historical parallel: past robotics growth phases exhibited long right tails in price; if product cycles repeat, capped-covered-call strategies are likely to miss substantial upside. Unintended consequence: heavy put-selling by retail/income funds can create liquidity squeezes on sharp downdrafts, amplifying drawdowns for short-dated sellers.

Key Decisions for Investors

• Establish a tactical cash-secured position: sell ISRG Feb 2026 555 puts (collect 18.90) sized 1–3% of NAV if willing to own at an effective 536.10; set rule to close/roll if ISRG falls >12% or IV increases >5 percentage points within 60 days.
• Implement a covered-call sleeve: buy ISRG up to 2–3% NAV and sell Feb 2026 580 calls (collect 24.50) to generate ~5.9% upside-to-call return; take profits and remove calls if ISRG >600 or ahead of any major FDA/earnings catalyst within 30 days.
• Use a collar for conservative exposure: buy ISRG and concurrently sell Feb 2026 580 calls and buy a protective put ~510 (1-yr) to cap downside to ~10–12% net cost; target this for taxable or concentrated positions and rebalance at 6–12 month intervals.
• Volatility arbitrage: if ISRG IV > realized by ≥3–5pts and no catalyst in next 90 days, sell a calendar/diagonal (long near stock, short longer-dated premium) sized to 0.5–1% NAV; reverse position if IV compresses < realized by 3pts.
• Monitor three trigger metrics for adjustments: surgical procedure volumes release (next 60–90 days), any FDA filings/approvals, and IV-realized spread crossing ±5 percentage points — act within 5 trading days of these triggers (close/roll or hedge).